Bone spurs, or osteophytes, are bony growths that develop on normal bones, often as a response to joint damage, aging, or chronic conditions like osteoarthritis. These growths can cause persistent pain, reduced mobility, and nerve compression, affecting millions globally. With an estimated 10% of adults over 50 living with bone spurs (2023 Global Rheumatology Association study), the condition is increasingly recognized as a significant healthcare challenge, driving demand for effective treatments and reshaping the bone spur market.

The primary growth drivers are demographic shifts and rising arthritis cases. The global population aged 65+ is projected to reach 1.5 billion by 2050 (WHO), up from 1 billion in 2023, amplifying bone spur risk. Osteoarthritis, a leading cause of bone spurs, affects 500 million people worldwide (WHO 2023), with 70% of sufferers developing spurs over time. To understand how these trends influence market strategies, stakeholders frequently reference the Bone Spur Treatment Advancements section in Market Research Future’s report, which synthesizes data on emerging therapies and regional demand.

The bone spur market is thriving, with Market Research Future estimating a 6.8% CAGR from 2024 to 2030, reaching $3.8 billion. This growth is fueled by increased diagnosis rates—attributed to better imaging access—and the launch of targeted treatments. For example, 2023 saw two new anti-inflammatory drugs approved specifically for bone spur-related pain, each capturing 5% of the market within a year. As aging populations expand and arthritis management improves, the need for bone spur treatments will only intensify, solidifying the market’s upward trajectory.

Challenges include underdiagnosis in early stages, where symptoms are mild or absent. A 2024 survey found that 40% of bone spur patients seek help only after experiencing severe pain, limiting the effectiveness of early interventions. However, awareness campaigns and improved primary care screening are addressing this gap. By 2026, WHO aims to reduce undiagnosed cases by 25%, boosting market growth as more patients access treatments.